Kamran Khalid, Vice President, Oncology Commercial Strategy, Thoracic at Bristol Myers Squibb, shared on LinkedIn:
“New chapter, same mission.
Today I’m joining Bristol Myers Squibb as Vice President, Oncology Commercial Strategy, Thoracic, fittingly during Lung Cancer Awareness Month.
Lung cancer remains one of oncology’s greatest areas of unmet need. Behind every statistic is a patient and a family hoping for more time and better options. That has driven my work, and it’s what I’m eager to carry into BMS.
Across 25 years in pharma, 20 of them focused on lung cancer, I’ve learned from and led talented teams at Lilly, OSI, Astellas, and AstraZeneca, always with the patient at the center. I’ve seen lung cancer care move from traditional chemotherapy and the early days of EGFR testing to computational pathology and antibody drug conjugates.
The progress is real, and there is so much more to do.
Thank you to my AstraZeneca colleagues for the partnership, and to my mentors, teammates, and family for their support.
To my new BMS colleagues, I’m honored to join a team committed to redefining what’s possible for patients with lung cancer.
Imagine a future where every person with lung cancer has more time to live, to explore, and to experience all that life offers.”
You may also be interested in:
Nikolaos A. Dallas: LiveWell Helps Us Build a More Accessible Lung Cancer Screening Pathway
Addressing Gaps in Lung Cancer Screening and Biomarker Testing – Bristol Myers Squibb
Bristol Myers Squibb Unifies R&D Under Cristian Massacesi in Major Leadership Restructuring
